Valneva

New Capabilities

Developer of the vaccine candidate; bearing 40% of development costs

The last Lyme disease vaccine was pulled from the market in 2002 after unfounded safety fears destroyed demand. Twenty-four years later, Pfizer and French biotech Valneva announced that their replacement candidate showed 73% efficacy in a Phase 3 trial of 9,000+ participants. They will seek FDA approval this year for a possible 2027 launch.

Updated May 30